What are the key details of the Bioxyne (ASX:BXN) deal with ADREXpharma?

Bioxyne has signed a two-year, $50 million exclusive supply agreement with German pharmaceutical company ADREXpharma. The contract, managed through Bioxyne’s subsidiary Breathe Life Sciences (BLS), involves supplying Australian GMP-manufactured medicinal cannabis flower and products to the German market.

How much revenue is guaranteed for Bioxyne (ASX:BXN) under this agreement?

The deal provides high revenue visibility with a $25 million minimum purchase commitment from ADREXpharma within the first 12 months. The contract includes an automatic renewal clause for a second year to reach the total $50 million valuation.

Why is the German market significant for Bioxyne (ASX:BXN)?

Germany is currently Europe’s largest and most developed medicinal cannabis market, serving as a primary gateway to the European Union. By securing an exclusive distribution partner, Bioxyne gains a defined sales pathway into a high-demand region.

What is the "Dr Watson" brand mentioned in the Bioxyne (ASX:BXN) announcement?

Dr Watson is Bioxyne’s proprietary medicinal cannabis brand. As part of this deal, ADREXpharma has been granted exclusive rights to distribute Dr Watson products within Germany.

What are the main bull and bear points for Bioxyne (ASX:BXN) after this news?

The bull case focuses on the massive revenue jump and the "minimum commitment" clause which de-risks the contract. The bear case involves "concentration risk," as a significant portion of Bioxyne’s future revenue now depends on a single partner and the regulatory stability of the German market.

How does this news change the investment thesis for Bioxyne (ASX:BXN)?

This agreement shifts Bioxyne from a speculative micro-cap explorer of the cannabis market to a revenue-generating international exporter with a validated product line. The transition to $25 million in committed annual revenue provides a fundamental floor for the company’s valuation that did not exist previously.

Bioxyne secures $50M German cannabis deal

Written by Jon CuthbertPublished May. 12 2026Last Updated May. 12 2026

Bioxyne (ASX:BXN) announced a major $50 million exclusive supply agreement with German pharmaceutical giant ADREXpharma.

Facilitated through Bioxyne’s wholly owned subsidiary, Breathe Life Sciences, the two-year contract marks an expansion into Germany, currently Europe’s largest and most developed medicinal cannabis market.

The agreement centres on the distribution of BLS’s premium, Australian GMP-manufactured cannabis flower and associated products, providing a robust sales pathway into the heart of the European Union.

The financial structure of the deal offers substantial near-term revenue visibility for the company.

It includes an initial $25 million minimum commitment within the first 12 months, featuring an automatic renewal clause for a further 12 months to reach the total $50 million valuation.

As part of the strategic partnership, Adrex has been granted exclusive German distribution rights for the proprietary Dr Watson brand.

The exclusivity is underpinned by the significant purchase commitments, ensuring targeted market penetration and brand loyalty in a highly competitive landscape.

This milestone follows an initial agreement executed in June 2025, reflecting a rapidly increasing demand for high-quality, GMP-certified medicinal products across Europe.

At the time of reporting, Bioxyne's share price was $0.083.